论文部分内容阅读
目的评价本院口服降糖药应用情况和变化趋势,为临床合理用药提供科学依据。方法对本院2012~2015年临床应用口服降糖药的品种、销售金额、用药频度(DDDs)、日均费用(DDC)等进行回顾性分析。结果 2012~2015年本院口服降糖药的销售金额总体呈上升趋势,各种口服降糖药的销售金额、DDDs均逐年增加,销售金额排名前3位的是二甲双胍胶囊、罗格列酮片和格列齐特片;DDDs排名前3位的是二甲双胍胶囊、格列齐特片和罗格列酮片;销售金额序与DDDs的排序比在0.67~1.50之间。结论本院口服降糖药的应用基本合理,适当引入新型口服降糖药物可满足不同病情的需要。
Objective To evaluate the application and change trend of oral hypoglycemic agents in our hospital and provide a scientific basis for clinical rational drug use. Methods The clinical data of oral hypoglycemic agents, sales amount, frequency of medication (DDDs) and daily average cost (DDC) in our hospital from 2012 to 2015 were analyzed retrospectively. Results The sales amount of oral hypoglycemic agents in our hospital generally showed an upward trend from 2012 to 2015. The sales amount and DDDs of various oral hypoglycemic agents increased year by year. The top three sales amounts were metformin capsules, rosiglitazone tablets And gliclazide tablets; DDDs ranked the top three are metformin capsules, gliclazide tablets and rosiglitazone tablets; sales order and DDDs sort ratio of between 0.67 ~ 1.50. Conclusion The application of oral hypoglycemic agents in our hospital is basically reasonable. Appropriate introduction of new oral hypoglycemic drugs can meet the needs of different conditions.